Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

MLA

F. Ceccherini Silberstein, et al. “Daclatasvir/Sofosbuvir and Ribavirin 800mg Flat Dose Is Highly Efficacy and Safe in Genotype 3 Compensated and Decompensated Cirrhotic Patients: The CLEO Experience.” Digestive and Liver Disease, vol. 49, Feb. 2017, p. e64. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........511e21e141c01f89a85e73e81f8ff3ae&authtype=sso&custid=ns315887.

APA

F. Ceccherini Silberstein, G. Cerasari, C.F. Perno, A. Moretti, L. Fondacaro, Giorgio Barbarini, F. Chiesara, Anna Claudia Pellicelli, R. Villani, C. D’Ambrosio, F.R. Ponziani, Sergio Babudieri, Maurizio Pompili, Rodolfo Sacco, Roberto Gulminetti, Pierluigi Tarquini, V. Pace Palitti, Vincenzo Messina, Antonio Izzi, … Serena Dell’Isola. (2017). Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience. Digestive and Liver Disease, 49, e64.

Chicago

F. Ceccherini Silberstein, G. Cerasari, C.F. Perno, A. Moretti, L. Fondacaro, Giorgio Barbarini, F. Chiesara, et al. 2017. “Daclatasvir/Sofosbuvir and Ribavirin 800mg Flat Dose Is Highly Efficacy and Safe in Genotype 3 Compensated and Decompensated Cirrhotic Patients: The CLEO Experience.” Digestive and Liver Disease 49 (February): e64. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........511e21e141c01f89a85e73e81f8ff3ae&authtype=sso&custid=ns315887.